key: cord-0867912-gzvrngoa
authors: Paschou, Stavroula A.; Goulis, Dimitrios G.; Lambrinoudaki, Irene; Papanas, Nikolaos
title: Menopausal hormone therapy for women with obesity in the era of COVID-19
date: 2020-06-25
journal: Case Rep Womens Health
DOI: 10.1016/j.crwh.2020.e00233
sha: 49681b476da03bc376fb457af53b796d7727adfa
doc_id: 867912
cord_uid: gzvrngoa

nan

estimated that over 1.9 billion adults (39%) worldwide are overweight, of whom 650 million are obese (13%) [1] . The problem is especially important in the western world and affects particularly postmenopausal women. Indeed, approximately 50% of the latter are overweight, of whom 25% are obese [2] [3] [4] . Obesity often leads to other morbidities, such as type 2 diabetes mellitus (T2DM), dyslipidaemia, and hypertension; additionally, it increases the risk of gynaecological malignancies, cardiovascular disease (CVD), thrombosis, osteoarthritis and musculoskeletal disease [1-4].

Vasomotor symptoms (VMS) are generally more common in obese women than in normalweight women. In the Study of Women's Health Across the Nation (SWAN), the likelihood of increased flushing was 1.27 times higher for any standard deviation (SD) increase in body fat percentage [5] . The women who gain weight during the transition to menopause are prone to develop VMS [2] [3] [4] [5] . Menopausal hormone therapy (MHT), including tibolone and the combination of conjugated equine estrogens and bazedoxifene (CE/BZA), is the most effective treatment for VMS associated with menopause at any age. However, benefits are more likely to outweigh risks if the treatment is initiated for symptomatic women before the age of 60 years or within 10 years after menopause [6] .

coronavirus SARS-CoV-2, a new thrombotic risk factor has been added to this list. COVID-19 is associated with a systemic inflammatory response, often accompanied by activation of coagulation, especially in those with clinical disease. This favours the appearance of thrombotic events and may produce various coagulopathies [8] .

Globally, the proportion of men and women who have tested positive for SARS-CoV-2 is comparable. However, men are about 60% more likely to develop severe illness or die from complications. It is not clear whether this is due to biological differences between the two genders, differences in behavioural habits, or differences in the rates of comorbidities [9] . People with obesity have low-grade inflammation and present comorbidities that adversely affect the outcomes of COVID-19. Early observations revealed that many patients, especially those who died from COVID-19, were obese. Indeed, obesity, especially when accompanied by T2DM, CVD or other physical, mental, and/or functional complications, has been persistently shown to be a predictor of severe COVID-19 illness and all-cause mortality [10, 11].

COVID-19 is likely to remain a problem for many months or even years until effective preventive or therapeutic strategies are developed. Since obesity and other comorbidities cannot be treated within a few months, the least the physicians can do is to be aware of such associations, and aim to provide the best holistic care possible. This approach should be applied for women taking or requesting MHT. Oral MHT increases the risk of thromboembolic disease. For women with confirmed or even suspected COVID-19, any type of systemic MHT should be stopped for the whole period of isolation or hospitalization. For hospitalized patients or those with reduced mobility at home, the use of low molecular weight heparin (LMWH) is recommended for a minimum of one week after hospital discharge or until full mobilization. The pre-COVID-19 MHT regimen should be recommenced only after full recovery and restoration of complete mobility, and it is advisable to consider changing to transdermal therapy [8] . In the era

Gains in body fat and vasomotor symptom reporting over the menopausal transition: the study of women's health across the nation

Revised global consensus statement on menopausal hormone therapy

Women's health initiative investigators. Estrogen plus progestin and risk of venous thrombosis

Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: Recommendations from the Spanish Menopause Society

Ginecología y Obstetricia and Sociedad Española de Trombosis y Hemostasia

Are we equal in adversity? Does Covid-19 affect women and men differently? Maturitas